Cepheid's test for vancomycin-resistant infections gets FDA OK
This article was originally published in Clinica
Cepheid's Xpert vanA test has received 510(k) clearance from the US FDA. It is the first rapid and accurate test released in the US for vanA, the gene most commonly associated with vancomycin-resistant Enterococci (VRE), the company claims. The test provides results in 45 minutes and runs on Cepheid's GeneXpert system. VRE accounts for around 30% of healthcare-associated infections, according to the US Centers for Disease Control and Prevention. Sunnyvale, California-based Cepheid also markets tests in the Xpert brand for Clostridium difficile, methicillin-resistant and -sensitive Staphylococcus aureus, and H1N1 (under an FDA emergency use authorisation).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.